BackAcumen Pharmaceuticals Overview

Acumen Pharmaceuticals Other Current Liabilities

Track Acumen Pharmaceuticals's other current liabilities ($14M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$13.80M
39.38% YoYΔ $-8.96M vs prior year quarter

Peer trimmed avg / median

Loading

Acumen Pharmaceuticals Other Current Liabilities History

Loading

Acumen Pharmaceuticals vs. peers: Other Current Liabilities Comparison

Loading

Acumen Pharmaceuticals Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Acumen Pharmaceuticals (ABOS) FAQ

Acumen Pharmaceuticals (ABOS) currently reports a other current liabilities of $14M as of June 2026. That compares with $23M in the prior-year period — down 39.4% year over year. Use the charts on this page to explore Acumen Pharmaceuticals's other current liabilities history and peer comparisons.

Acumen Pharmaceuticals's other current liabilities decreased from $23M to $14M — a 39.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Acumen Pharmaceuticals reported $14M in other current liabilities as of June 2026. That compares with $23M in the prior-year period — down 39.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $14M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Acumen Pharmaceuticals, and consider following ABOS for alerts when major investors trade the stock.

Acumen Pharmaceuticals is classified in the Healthcare sector. On other current liabilities, it currently shows $14M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ABOS with unrelated industries.